GlassScriptPhysician profile
Michael B Talburt
NPI 1639219777
$1,160.71
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $156.95 | 2021 | |
| Abbvie INC. | $154.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $148.01 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $124.43 | 2021 | |
| Lundbeck LLC | $89.95 | 2021 | |
| Jazz Pharmaceuticals INC. | $72.35 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.00 | 2021 | |
| Bausch Health US, LLC | $44.95 | 2021 | |
| Acadia Pharmaceuticals INC | $37.75 | 2021 | |
| Merck Sharp & Dohme LLC | $36.12 | 2021 | |
| Avanir Pharmaceuticals, INC. | $30.78 | 2021 | |
| Eisai INC. | $27.61 | 2021 | |
| Neurocrine Biosciences, INC. | $18.01 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Talburt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.